共 295 条
[41]
Fassas A(2017)Modified CVAD and modified CBAD compared to high-dose cyclophosphamide for peripheral blood stem cell mobilization in patients with multiple myeloma Eur J Haematol 98 388-625
[42]
Takeyama K(2009)Comparison of high-dose CY and growth factor with growth factor alone for mobilization of stem cells for transplantation in patients with multiple myeloma Bone Marrow Transplant 43 619-1528
[43]
Ohto H(2020)CD34+ cell mobilization, blood graft composition, and posttransplant recovery in myeloma patients compared to non-Hodgkin's lymphoma patients: results of the prospective multicenter GOA study Transfusion 60 1519-1056
[44]
Danylesko I(2008)Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation Biol Blood Marrow Transplant 14 1045-128
[45]
Sareli R(2014)The five “Ws” for bone pain due to the administration of granulocyte-colony stimulating factors (G-CSFs) Crit Rev Oncol Hematol 89 112-35
[46]
Varda-Bloom N(2003)A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy Ann Oncol 14 29-1311
[47]
Yerushalmi R(2008)Factors associated with peripheral blood stem cell yield in volunteer donors mobilized with granulocyte colony-stimulating factors: the impact of donor characteristics and procedural settings Biol Blood Marrow Trans 14 1305-124
[48]
Shem-Tov N(2003)Stem cell mobilization by G-CSF in solid and hematological malignancies: single daily dose is better than split dose in obese patients J Clin Apher 18 120-1005
[49]
Shimoni A(2012)Higher BMI is not a barrier to stem cell mobilization with standard doses of plerixafor and G-CSF Bone Marrow Trans 47 1003-7091
[50]
Steinberg M(2005)Granulocyte colony-stimulating factor: a novel mediator of T cell tolerance J Immunol 175 7085-891